Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping

Journal of Clinical Microbiology

Volumn 52, Issue 11, 2014, Pages 4043-4046

  Drouot, Emilien ^a   Piret, Jocelyne ^a   Lebel, Marc H ^b   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; ANTIVIRUS AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHILD; CYTOMEGALOVIRUS INFECTION; EC50; FEMALE; GENETIC VARIABILITY; GRAFT RECIPIENT; HUMAN; HUMAN CELL; INFECTION PREVENTION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRESCHOOL CHILD; UL54 GENE; UL97 GENE; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS REPLICATION; CYTOMEGALOVIRUS; DRUG EFFECTS; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPROMIZED PATIENT; ISOLATION AND PURIFICATION; MISSENSE MUTATION; PHYSIOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MUTATION, MISSENSE; VIRUS REPLICATION;

EID: 84908333260     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02205-14     Document Type: Article

References (18)

1. Sedky M, Mekki Y, Mialou V, Bleyzac N, Girard S, Salama E, Abdel Rahman H, Bertrand Y. 5 December 2013. Cytomegalovirus infection in pediatric allogenic hematopoietic stem cell transplantation. A single center experience. Pediatr. Hematol. Oncol. http://dx.doi.org/10.3109/08880018.2013.859188.
2. Andrei G, De Clercq E, Snoeck R. 2009. Drug targets in cytomegalovirus infection. Infect. Disord. Drug Targets 9:201-222. http://dx.doi.org/10.2174/187152609787847758.
3. Boeckh M. 2011. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology 2011:305-309. http://dx.doi.org/10.1182/asheducation-2011.1.305.
4. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712. http://dx.doi.org/10.1128/CMR.00009-10.
5. Erice A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12:286-297.
6. Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39. http://dx.doi.org/10.1086/375743.
7. Chou S, Van Wechel LC, Lichy HM, Marousek GI. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49: 2710-2715. http://dx.doi.org/10.1128/AAC.49.7.2710-2715.2005.
8. Chou S, Marousek GI, Van Wechel LC, Li S, Weinberg A. 2007. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob. Agents Chemother. 51:4160-4162. http://dx.doi.org/10.1128/AAC.00736-07.
9. Scott GM, Weinberg A, Rawlinson WD, Chou S. 2007. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother. 51:89-94. http://dx.doi.org/10.1128/AAC.00633-06.
10. Blackman SC, Lurain NS, Witte DP, Filipovich AH, Groen P, Schleiss MR. 2004. Emergence and compartmentalization of fatal multi-drug resistant cytomegalovirus infection in a patient with autosomal-recessive severe combined immune deficiency. J. Pediatr. Hematol. Oncol. 26:601-605. http://dx.doi.org/10.1097/01.mph.0000135283.77668.6a.
11. Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL. 2006. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl. Infect. Dis. 8:38-43. http://dx.doi.org/10.1111/j.1399-3062.2006.00128.x.
12. Germi R, Mariette C, Alain S, Lupo J, Thiebaut A, Brion JP, Epaulard O, Saint Raymond C, Malvezzi P, Morand P. 2014. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral Res. 101:57-61. http://dx.doi.org/10.1016/j.antiviral.2013.10.014.
13. Borst EM, Hahn G, Koszinowski UH, Messerle M. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329.
14. Drouot E, Piret J, Boivin G. 2013. Novel method based on "en passant" mutagenesis coupled with a Gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations. J. Clin. Microbiol. 51:3216-3224. http://dx.doi.org/10.1128/JCM.01275-13.
15. Tischer BK, Smith GA, Osterrieder N. 2010. En passant mutagenesis: a two step markerless red recombination system. Methods Mol. Biol. 634: 421-430. http://dx.doi.org/10.1007/978-1-60761-652-8-30. 20677001.
16. Chou S, Waldemer RH, Senters AE, Michels KS, Kemble GW, Miner RC, Drew WL. 2002. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 185:162-169. http://dx.doi.org/10.1086/338362.
17. Chevillotte M, Schubert A, Mertens T, von Einem J. 2009. Fluorescence based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness. Antimicrob. Agents Chemother. 53:3752-3761. http://dx.doi.org/10.1128/AAC.00165-09.
18. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhauser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kolling K, Stobernack HP, Lischka P, Zimmermann H, Rubsamen-Schaeff H, Champlin RE, Ehninger G, AIC246 Study Team. 2014. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N. Engl. J. Med. 370:1781-1789. http://dx.doi.org/10.1056/NEJMoa1309533.